Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

PURPOSE: This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND ME...

Повний опис

Бібліографічні деталі
Автори: Ramalingam, S, Blackhall, F, Krzakowski, M, Barrios, C, Park, K, Bover, I, Seog Heo, D, Rosell, R, Talbot, D, Frank, R, Letrent, S, Ruiz-Garcia, A, Taylor, I, Liang, J, Campbell, A, O'Connell, J, Boyer, M
Формат: Journal article
Мова:English
Опубліковано: 2012

Схожі ресурси

Схожі ресурси